Brokerages Set DexCom, Inc. (NASDAQ:DXCM) PT at $86.61

DexCom, Inc. (NASDAQ:DXCM) has been given a consensus recommendation of “Moderate Buy” by the twenty-eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $86.6087.

DXCM has been the topic of a number of recent research reports. Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, December 16th. Truist Financial reaffirmed a “buy” rating and set a $82.00 target price (down from $94.00) on shares of DexCom in a report on Monday, November 3rd. BTIG Research dropped their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Argus reduced their price target on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Piper Sandler set a $75.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st.

Insider Buying and Selling

In related news, Director Richard Alexander Collins sold 3,948 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $55.17, for a total value of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares of the company’s stock, valued at $2,096,128.98. The trade was a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach acquired 18,200 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the transaction, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Keel Point LLC raised its position in DexCom by 67.4% during the third quarter. Keel Point LLC now owns 6,280 shares of the medical device company’s stock valued at $423,000 after purchasing an additional 2,528 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of DexCom in the 3rd quarter valued at $140,000. Allworth Financial LP raised its holdings in shares of DexCom by 29.7% during the 3rd quarter. Allworth Financial LP now owns 4,936 shares of the medical device company’s stock worth $332,000 after buying an additional 1,129 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares in the last quarter. Finally, Swiss Life Asset Management Ltd lifted its position in shares of DexCom by 0.9% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 85,970 shares of the medical device company’s stock worth $5,785,000 after buying an additional 759 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

DXCM opened at $67.57 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The business has a fifty day simple moving average of $64.07 and a 200 day simple moving average of $73.19. DexCom has a 1 year low of $54.11 and a 1 year high of $93.25. The company has a market capitalization of $26.35 billion, a PE ratio of 37.54, a price-to-earnings-growth ratio of 1.45 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business earned $0.45 EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. Research analysts expect that DexCom will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.